Income Tax Expense (Benefit) of Lineage Cell Therapeutics, Inc. from 31 Mar 2013 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Lineage Cell Therapeutics, Inc. annual and quarterly Income Tax Expense (Benefit) in USD history and change rate from 31 Mar 2013 to 31 Dec 2025.
  • Lineage Cell Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending 31 Dec 2024 was $0.
  • Lineage Cell Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending 31 Dec 2024 was $0.
  • Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2025 was $5,280,000.
  • Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $0.
  • Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $1,803,000, a 433% decline from 2022.
Source SEC data
View on sec.gov
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $5,280,000 -$5,280,000 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $0 +$1,803,000 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $1,803,000 -$2,344,000 -433% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
2022 $541,000 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2020 $1,239,000 +$6,168,000 +83% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $7,407,000 -$7,753,000 -2241% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $346,000 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY

Lineage Cell Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $0 $0 $0 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $0 $0 $0 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $0 $0 $0 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $0 $0 +$1,803,000 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $1,803,000 $0 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2025 2024 FY
Q3 2023 $0 -$541,000 -100% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $0 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,803,000 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $541,000 +$1,553,000 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q3 2021 $1,012,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q3 2019 $1,000,000 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q1 2019 $4,384,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q3 2017 $0 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2017 2017 Q3
Q3 2014 $2,312,693 -$2,312,693 01 Jul 2014 30 Sep 2014 10-Q 07 Nov 2014 2014 Q3
Q2 2014 $1,513,258 -$1,513,258 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2014 2014 Q2
Q1 2014 $1,349,026 -$1,349,026 01 Jan 2014 31 Mar 2014 10-Q 12 May 2014 2014 Q1
Q3 2013 $0 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2014 Q3
Q2 2013 $0 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2
Q1 2013 $0 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.